All In Biotech

Drug Trial Radar · NCT03985410

Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

A Randomized, Three Period Crossover Thorough QT (TQT) Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers

Last checked: Nov 20, 2026Latest source record: Aug 30, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

32

Actual

Start

May 23, 2019

Primary completion

Jul 24, 2019

Study completion Jul 24, 2019

Sponsor

Lead sponsor
Entasis TherapeuticsIndustry
Sponsor type
Industry
First posted
Jun 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the effects of supratherapeutic ETX2514 plasma concentrations on the heart rate-corrected QT interval (QTc).

Conditions

  • Acinetobacter Baumannii-calcoaceticus Complex Infections

Interventions

  • ETX2514Drug

    intravenous infusion

  • PlaceboDrug

    intravenous infusion

  • moxifloxacinDrug

    oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Placebo-corrected change from Baseline in Fridericia-corrected QTc (QTcF) (ΔΔQTcF)Time frame: Baseline; up to Day 22

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Pharmaron Clinical Pharmacology Center

    Baltimore, Maryland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.